At a Glance
Section 32 was founded in 2016 by Bill Maris, the former managing partner of Google Ventures, with a mission to invest in companies at the intersection of healthcare and deep technology. The firm takes a science-first approach, backing entrepreneurs who are leveraging breakthrough technologies like artificial intelligence, machine learning, and advanced biotechnology to tackle some of healthcare's most challenging problems. Under Maris's leadership, Section 32 has built a reputation for making bold bets on transformative companies, often investing in areas where traditional healthcare investors might be hesitant to venture. The firm's portfolio spans digital health platforms, biotech companies developing novel therapeutics, and deep tech companies working on advanced materials and manufacturing. Section 32 is known for its patient capital approach and willingness to support companies through multiple funding rounds as they work to bring revolutionary technologies to market.
“Invests in companies at the intersection of healthcare, biology, and technology that have the potential to fundamentally improve human life.”
Section 32 primarily invests at the Seed, Series A, Series B+ stages. This means they focus on companies that are building their initial product and finding product-market fit.
Section 32 is headquartered in Palo Alto, CA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Section 32 focuses on investments in Digital Health, Biotech, AI, Deeptech. Their portfolio reflects deep expertise and networks within these sectors.
Section 32's typical investment check size ranges from $1M to $30M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Section 32 manages approximately $1B in assets under management (AUM) across their funds.